Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer

✍ Scribed by Saeki, Hiroshi; Kawaguchi, Hidetoshi; Kitamura, Kaoru; Ohno, Shinji; Sugimachi, Keizo

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 127 KB
• Volume: 69
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199812)69:4<224::aid-jso6>3.0.co;2-i

✦ Synopsis

Background and objectives:

Hyperthermochemoradiotherapy (hcr) has been performed on numerous patients with esophageal cancer. the purpose of this study is to demonstrate the recent advances in hcr.

Methods:

From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (cr) or hcr were classified according to the anticancer agent that was administered (cr; group a given bleomycin (blm); group b given cis-diamminedichloroplatinum (ii) (cddp), hcr; group c given blm; and group d given cddp). the local response and the long-term results were investigated.

Results:

The cases in which cr or hcr was evaluated to be effective numbered 44 (48.4%) in group a, 22 (73.3%) in group b, 79 (63.7%) in group c, and 36 (73.5%) in group d. a significant difference was observed between groups a and b (p < 0.05). the highest incidence of markedly effective cases was observed in group d. the 5-year survival rates for the group a and b patients were 17.2% and 43.9%, respectively (p < 0.01), while the same rates for those of groups c and d were 25.6% and 57.8%, respectively (p < 0.05). our results thus showed cddp to have a greater effect than blm, while hcr had a greater effect than cr.

Conclusions:

Preoperative hcr has improved thanks to recent advances in anticancer agents.